Evinacumab (Regeneron) appears to have a dramatic effect on low-density lipoprotein (LDL) cholesterol levels in patients with homozygous familial hypercholesterolemia (HoFH) with little or no LDL receptor activity, suggests a post hoc analysis of phase 3 trial data.
The results, which one expert described as a “game changer” for these patients, were presented at the European Atherosclerosis Society 2020 Virtual Congress on October 5, held online this year because of the COVID-19 pandemic.
The phase 3 ELIPSE trial showed that evinacumab, a human monoclonal antibody inhibitor of angiopoietin-like 3 (ANGPTL3), given intravenously every 4 weeks reduced LDL cholesterol levels in HoFH patients by an average of 47%.
As reported by theheart.org | Medscape Cardiology, the treatment, which was generally well tolerated, was also effective in the approximately one third of patients with minimal residual LDL receptor activity.
Now, Frederick Raal, MD, PhD, the University of the Witwatersrand, Johannesburg, South Africa, presented a post hoc analysis of 10 patients with less than 2% functional LDL receptor activity. These patients experienced an even greater reduction of 72% over placebo.
Raal said that, taken together, the results are “remarkable in these very, very difficult to treat patients,” who have “a very unmet need.” He noted that the drug is “generally well tolerated.”
“Evinacumab may provide an effective treatment option for patients with HoFH who are unable to reach target LDL cholesterol levels despite multiple lipid lowering therapies, with or without apheresis,” Raal concluded.
Anne C. Goldberg, MD, a lipidologist and professor of medicine at Washington University in St. Louis, St. Louis, Missouri, told theheart.org | Medscape Cardiology that HoFH patients with little or no LDL receptor activity, who number in the hundreds around the world, are a “very difficult group to treat because things don’t work.”
She pointed out that over 90% of patients in the trial were aged in their 30s and that the majority of them already had heart disease.
“So if you have something where you could start treating them relatively young and safely, theoretically, you could try to prevent some of these terrible cardiovascular outcomes in this group,” she said.
Goldberg highlighted that a drug such as evinacumab that can lower LDL levels in patients, often “for the first time ever, is quite a game changer.” She said that this was also seen with anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) therapies among patients with HoFH.
She also noted that the safety profile of evinacumab is encouraging.
“There are always going to be people with problems with anything, but there are not a lot of side effects,” she said, underlining that this is not seen “that often.”
Summarizing, Goldberg said that evinacumab “just seems to work, I think pretty nicely,” although she added that it “would be nice if we had a better idea about the mechanism of action, because it’s still a bit unclear how it works.”
Raal explained that HoFH is rare genetic disorder primarily due to mutations in the LDL receptor that result in highly elevated